Impact of Host NF-kB Signaling in Radiation Therapy

宿主 NF-kB 信号传导在放射治疗中的影响

基本信息

  • 批准号:
    10434953
  • 负责人:
  • 金额:
    $ 36.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT Investigation of cytoplasmic-to-nuclear (C→N) NF-κB signaling pathways induced by various cell surface receptors has significantly expanded the knowledge regarding the role of this transcription factor family in regulating immune/inflammatory responses and tumorigenesis. By contrast, the physiological role of DNA damage-induced nuclear-to-cytoplasmic (N→C) NF-κB signaling remains poorly understood. The proposed study will fill this knowledge gap by elucidating a surprising and crucial role of N→C NF-κB signaling in sustaining anti-tumor CD8 T cell responses during radiotherapy (RT) in vivo. The current proposal utilizes a genetically modified mouse model that selectively disables N→C NF-κB signaling in vivo. Our preliminary data show that radiation therapy can induce sustained regression of syngeneic tumors in a manner dependent on CD8 T cells. We also found that a special type of memory CD8 T cells implicated in tumor control is expanded in this mouse model. Finally, we have generated an encouraging data with an NF-kB DNA binding inhibitor to induce sustained tumor regression following radiation therapy. Based on these observations, we hypothesize that inhibition of N→C NF-κB signaling in the host improve radiation therapy via generation of tumor antigen-specific memory CD8 T cells. We will test this hypothesis by define the cellular mechanism of sustained tumor control mediated by inhibiting host N→C NF-κB signaling in radiation therapy (Aim 1), elucidate the molecular mechanism of sustained tumor control mediated by inhibiting host N→C NF-κB signaling in radiation therapy (Aim 2) and target host N→C NF-κB signaling with a chemical inhibitor to improve radiation therapy (Aim 3). The proposed study is significant because the physiological role of N→C NF-κB signaling in modulating host tumor response is completely undefined and this study will fill this knowledge gap. It is innovative because a new mouse model and a novel chemical inhibitor currently undergoing Phase 2 clinical trials will be employed. Finally, a high impact is expected because chemical targeting of N→C NF-κB signaling by the above inhibitor may expedite timely translation to clinical trials.
项目总结/摘要 不同细胞表面活性剂诱导的C→N NF-κB信号通路的研究 受体的研究极大地扩展了关于该转录因子家族在 调节免疫/炎症反应和肿瘤发生。相比之下,DNA的生理作用 损伤诱导的核-胞质(N→C)NF-κB信号转导仍然知之甚少。拟议 这项研究将通过阐明N→C NF-κB信号转导在维持NF-κB活性中令人惊讶的关键作用来填补这一知识空白。 体内放疗(RT)期间的抗肿瘤CD 8 T细胞反应。目前的建议利用基因 改良的小鼠模型,其在体内选择性地使N→C NF-κB信号传导失活。初步数据显示, 放射治疗可以以依赖于CD 8 T细胞的方式诱导同源肿瘤的持续消退。 我们还发现,一种特殊类型的记忆性CD 8 T细胞在肿瘤控制中被扩增, 模型最后,我们已经产生了一个令人鼓舞的数据与NF-κ B DNA结合抑制剂,以诱导持续的 放射治疗后肿瘤消退。基于这些观察,我们假设, 宿主N→C NF-κB信号通路通过产生肿瘤抗原特异性记忆促进放射治疗 CD 8 T细胞。我们将通过定义持续的肿瘤控制介导的细胞机制来验证这一假设。 通过抑制宿主N→C NF-κB信号通路(Aim 1),阐明放射治疗中NF-κB的分子机制, 在放射治疗中通过抑制宿主N→C NF-κB信号传导介导的持续肿瘤控制(Aim 2)和靶点 宿主N→C NF-κB信号传导与化学抑制剂,以改善放射治疗(目的3)。拟定研究 这是因为N→C NF-κB信号在调节宿主肿瘤反应中的生理作用是重要的, 完全不确定,这项研究将填补这一知识空白。它是创新的,因为一种新的小鼠模型, 将使用一种目前正在进行2期临床试验的新型化学抑制剂。最后,高影响是 这是因为上述抑制剂化学靶向N→C NF-κB信号传导可能会及时加速 转化为临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHIGEKI MIYAMOTO其他文献

SHIGEKI MIYAMOTO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHIGEKI MIYAMOTO', 18)}}的其他基金

Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
  • 批准号:
    10297956
  • 财政年份:
    2021
  • 资助金额:
    $ 36.89万
  • 项目类别:
Impact of Host NF-kB Signaling in Radiation Therapy
宿主 NF-kB 信号传导在放射治疗中的影响
  • 批准号:
    10665545
  • 财政年份:
    2021
  • 资助金额:
    $ 36.89万
  • 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
  • 批准号:
    10439626
  • 财政年份:
    2020
  • 资助金额:
    $ 36.89万
  • 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
  • 批准号:
    10626002
  • 财政年份:
    2020
  • 资助金额:
    $ 36.89万
  • 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
  • 批准号:
    10029257
  • 财政年份:
    2020
  • 资助金额:
    $ 36.89万
  • 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
  • 批准号:
    10187534
  • 财政年份:
    2020
  • 资助金额:
    $ 36.89万
  • 项目类别:
Regulation of NEMO modifications in radiation-induced NF-kB signaling
辐射诱导的 NF-kB 信号传导中 NEMO 修饰的调节
  • 批准号:
    8656285
  • 财政年份:
    2013
  • 资助金额:
    $ 36.89万
  • 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
  • 批准号:
    7986606
  • 财政年份:
    2010
  • 资助金额:
    $ 36.89万
  • 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
  • 批准号:
    8098970
  • 财政年份:
    2010
  • 资助金额:
    $ 36.89万
  • 项目类别:
Regulation of NF-kappaB by Small Ubiquitin-Like Modifiers
小泛素样修饰剂对 NF-kappaB 的调节
  • 批准号:
    8505491
  • 财政年份:
    2010
  • 资助金额:
    $ 36.89万
  • 项目类别:

相似海外基金

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
通过间质局部消融免疫疗法增强全身抗肿瘤反应,与转移性胰腺肿瘤的免疫检查点疗法协同作用
  • 批准号:
    10580071
  • 财政年份:
    2022
  • 资助金额:
    $ 36.89万
  • 项目类别:
Development of new cancer treatment utilizing the enhancement of antitumor response caused by allo reaction
利用同种异体反应增强抗肿瘤反应开发新的癌症治疗方法
  • 批准号:
    20K17649
  • 财政年份:
    2020
  • 资助金额:
    $ 36.89万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Role of CD4 T cells and APCs in the induction and maintenance of an effective antitumor response
CD4 T 细胞和 APC 在诱导和维持有效抗肿瘤反应中的作用
  • 批准号:
    nhmrc : 143674
  • 财政年份:
    2001
  • 资助金额:
    $ 36.89万
  • 项目类别:
    NHMRC Project Grants
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
  • 批准号:
    2377164
  • 财政年份:
    1997
  • 资助金额:
    $ 36.89万
  • 项目类别:
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
  • 批准号:
    2712876
  • 财政年份:
    1997
  • 资助金额:
    $ 36.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了